171 related articles for article (PubMed ID: 8556529)
41. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide.
Schlageter AM; Kozel TR
Infect Immun; 1990 Jun; 58(6):1914-8. PubMed ID: 2187813
[TBL] [Abstract][Full Text] [Related]
42. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection.
Feldmesser M; Casadevall A
J Immunol; 1997 Jan; 158(2):790-9. PubMed ID: 8992996
[TBL] [Abstract][Full Text] [Related]
43. Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide.
Spiropulu C; Eppard RA; Otteson E; Kozel TR
Infect Immun; 1989 Oct; 57(10):3240-2. PubMed ID: 2476401
[TBL] [Abstract][Full Text] [Related]
44. Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi?
Pirofski LA; Casadevall A
Zentralbl Bakteriol; 1996 Aug; 284(4):475-95. PubMed ID: 8899968
[TBL] [Abstract][Full Text] [Related]
45. The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.
Nakouzi A; Zhang T; Oscarson S; Casadevall A
Vaccine; 2009 Jun; 27(27):3513-8. PubMed ID: 19464529
[TBL] [Abstract][Full Text] [Related]
46. Murine monoclonal antibodies recognizing a non-capsular antigen that distinguishes between Cryptococcus neoformans var. neoformans and C. neoformans var. gattii.
Hamilton AJ; Bartholomew MA; Figueroa J; Fenelon LE; Hay RJ
Trans R Soc Trop Med Hyg; 1991; 85(1):123-7. PubMed ID: 2068741
[TBL] [Abstract][Full Text] [Related]
47. Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans.
Feldmesser M; Kress Y; Casadevall A
J Infect Dis; 1998 Jun; 177(6):1639-46. PubMed ID: 9607844
[TBL] [Abstract][Full Text] [Related]
48. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.
Beenhouwer DO; Shapiro S; Feldmesser M; Casadevall A; Scharff MD
Infect Immun; 2001 Oct; 69(10):6445-55. PubMed ID: 11553589
[TBL] [Abstract][Full Text] [Related]
49. Antifungal activity of a human antiglucuronoxylomannan antibody.
Zhong Z; Pirofski LA
Clin Diagn Lab Immunol; 1998 Jan; 5(1):58-64. PubMed ID: 9455881
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis: implications for passive immunotherapy.
Goldman DL; Casadevall A; Zuckier LS
J Med Vet Mycol; 1997; 35(4):271-8. PubMed ID: 9292424
[TBL] [Abstract][Full Text] [Related]
51. Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies.
MacGill TC; MacGill RS; Kozel TR
Infect Immun; 2001 Feb; 69(2):1189-91. PubMed ID: 11160020
[TBL] [Abstract][Full Text] [Related]
52. Strain-related differences in antibody-mediated changes in gene expression are associated with differences in capsule and location of binding.
McClelland EE; Casadevall A
Fungal Genet Biol; 2012 Mar; 49(3):227-34. PubMed ID: 22327012
[TBL] [Abstract][Full Text] [Related]
53. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.
Zebedee SL; Koduri RK; Mukherjee J; Mukherjee S; Lee S; Sauer DF; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1994 Jul; 38(7):1507-14. PubMed ID: 7979280
[TBL] [Abstract][Full Text] [Related]
54. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide.
Valadon P; Nussbaum G; Oh J; Scharff MD
J Immunol; 1998 Aug; 161(4):1829-36. PubMed ID: 9712050
[TBL] [Abstract][Full Text] [Related]
55. Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.
Gates-Hollingsworth MA; Kozel TR
Mol Microbiol; 2009 Oct; 74(1):126-138. PubMed ID: 19758241
[TBL] [Abstract][Full Text] [Related]
56. Unexpected diversity in the fine specificity of monoclonal antibodies that use the same V region gene to glucuronoxylomannan of Cryptococcus neoformans.
McFadden DC; Casadevall A
J Immunol; 2004 Mar; 172(6):3670-7. PubMed ID: 15004170
[TBL] [Abstract][Full Text] [Related]
57. Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice.
Yuan RR; Spira G; Oh J; Paizi M; Casadevall A; Scharff MD
Infect Immun; 1998 Mar; 66(3):1057-62. PubMed ID: 9488395
[TBL] [Abstract][Full Text] [Related]
58. Finite-element model of interaction between fungal polysaccharide and monoclonal antibody in the capsule of Cryptococcus neoformans.
Rakesh V; Schweitzer AD; Zaragoza O; Bryan R; Wong K; Datta A; Casadevall A; Dadachova E
J Phys Chem B; 2008 Jul; 112(29):8514-22. PubMed ID: 18588334
[TBL] [Abstract][Full Text] [Related]
59. Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans.
Nussbaum G; Yuan R; Casadevall A; Scharff MD
J Exp Med; 1996 Apr; 183(4):1905-9. PubMed ID: 8666947
[TBL] [Abstract][Full Text] [Related]
60. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance.
Zaragoza O; Casadevall A
Cell Microbiol; 2006 Dec; 8(12):1862-76. PubMed ID: 16824038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
